Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600627787> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- W2600627787 abstract "e19131 Background: The platinum doublet is standard first-line therapy in advanced NSCLC. Over the past decade, well-tolerated second-line therapies have been approved, including erlotinib and pemetrexed. We hypothesize that the introduction of less-toxic chemotherapy has increased treatment of advanced NSCLC, resulting in improved survival. Methods: The BC Cancer Agency provides cancer care to a population of 4.5 million. A retrospective review was conducted of all referred stage IIIB/IV patients in four 1-yr time cohorts; C1 baseline (1998) and 6 months after the provincial approval of C2 docetaxel (2001), C3 erlotinib (2006) and C4 pemetrexed (2007). Results: 2,623 patients were referred and 720 had systemic therapy. Characteristics: M/F 55%/45%, median age 67 (33-101), ECOG <=1/>=2/unknown 33%/56%/11%, never/former/current/unknown smoker 9%/35%/36%/20%, squam/nonsquam/NOS 18%/41%/41%. More patients received first-line chemotherapy over time; 16%, 23%, 34%, 33% C1-4 respectively. In C1 to C4 uptake of second line (21%, 27%, 38%, 55%) and third line (10%, 10% 14%, 18%) increased. In C1 the most common first-line doublet was cis/vino (70%) and in C4, cis/gem (45%). Second-line doce was frequently used in C2 (51%) but usage decreased in C4 to 7% vs. erlo 50% and pem 26%. In the >=70 group (n=1,118), first-line usage increased from C1 9% to C4 19% and second-line in the C2 (doce) 4% to C4 (erlo+pem avail) 56%. The increased use of systemic therapy was associated with improved survival in all patients: C1 4.56 m vs C4 4.98 m (p=0.004) and treated patients; C1 9.48 m vs C4 12.07 m (p=0.014) and the >= 70 group; C1 9.7 m vs C4 12.5 m (p=0.07). Conclusions: This population-based data set represents the trend of treatments over time in a large geographical area, including community and tertiary care cancer treatment sites. The introduction of less-toxic systemic therapy for advanced NSCLC resulted in an increased proportion of patients treated with first-line chemotherapy and an even greater increase in second-/third-line treatment. This trend was particularly evident in the elderly. Associated with this was a significant improvement in overall survival for all subsets." @default.
- W2600627787 created "2017-04-07" @default.
- W2600627787 creator A5017551211 @default.
- W2600627787 creator A5041084323 @default.
- W2600627787 creator A5048614301 @default.
- W2600627787 creator A5087116862 @default.
- W2600627787 creator A5088331751 @default.
- W2600627787 creator A5091168182 @default.
- W2600627787 date "2013-05-20" @default.
- W2600627787 modified "2023-10-12" @default.
- W2600627787 title "Less toxic chemotherapy on the uptake of all lines of chemotherapy in advanced non-small cell lung cancer: A 10-year retrospective population-based review." @default.
- W2600627787 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.e19131" @default.
- W2600627787 hasPublicationYear "2013" @default.
- W2600627787 type Work @default.
- W2600627787 sameAs 2600627787 @default.
- W2600627787 citedByCount "0" @default.
- W2600627787 crossrefType "journal-article" @default.
- W2600627787 hasAuthorship W2600627787A5017551211 @default.
- W2600627787 hasAuthorship W2600627787A5041084323 @default.
- W2600627787 hasAuthorship W2600627787A5048614301 @default.
- W2600627787 hasAuthorship W2600627787A5087116862 @default.
- W2600627787 hasAuthorship W2600627787A5088331751 @default.
- W2600627787 hasAuthorship W2600627787A5091168182 @default.
- W2600627787 hasConcept C121608353 @default.
- W2600627787 hasConcept C126322002 @default.
- W2600627787 hasConcept C143998085 @default.
- W2600627787 hasConcept C167135981 @default.
- W2600627787 hasConcept C2776256026 @default.
- W2600627787 hasConcept C2776694085 @default.
- W2600627787 hasConcept C2908647359 @default.
- W2600627787 hasConcept C71924100 @default.
- W2600627787 hasConcept C99454951 @default.
- W2600627787 hasConceptScore W2600627787C121608353 @default.
- W2600627787 hasConceptScore W2600627787C126322002 @default.
- W2600627787 hasConceptScore W2600627787C143998085 @default.
- W2600627787 hasConceptScore W2600627787C167135981 @default.
- W2600627787 hasConceptScore W2600627787C2776256026 @default.
- W2600627787 hasConceptScore W2600627787C2776694085 @default.
- W2600627787 hasConceptScore W2600627787C2908647359 @default.
- W2600627787 hasConceptScore W2600627787C71924100 @default.
- W2600627787 hasConceptScore W2600627787C99454951 @default.
- W2600627787 hasLocation W26006277871 @default.
- W2600627787 hasOpenAccess W2600627787 @default.
- W2600627787 hasPrimaryLocation W26006277871 @default.
- W2600627787 isParatext "false" @default.
- W2600627787 isRetracted "false" @default.
- W2600627787 magId "2600627787" @default.
- W2600627787 workType "article" @default.